J. David Joyner - 30 Nov 2024 Form 4/A - Amendment Insider Report for CVS HEALTH Corp (CVS)

Role: President and CEO, Director
Signature: /s/ J. David Joyner
Issuer symbol: CVS
Transactions as of: 30 Nov 2024
Net transactions value: +$107,194,007
Form type: 4/A - Amendment
Filing time: 26 Dec 2024, 16:11:53 UTC
Date Of Original Report: 03 Dec 2024
Previous filing: 03 Apr 2024
Next filing: 03 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CVS	Common Stock						40,681	30 Nov 2024	Direct
holding	CVS	Common Stock (Restricted)						44,241	30 Nov 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CVS	Premium Stock Option	Award	$71,820,000	+1,000,000		$71.82	1,000,000	30 Nov 2024	Common Stock	1,000,000	$71.82	Direct	F1
transaction	CVS	Premium Stock Appreciation Right	Award	$35,374,007	+492,537		$71.82	492,537	30 Nov 2024	Common Stock	492,537	$71.82	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 20, 2024, the Issuer made certain administrative modifications to the Reporting Person's November 30, 2024 grant agreement, confirming that the Reporting Person was granted a stock option to acquire 1,000,000 shares of Issuer common stock and a stock-settled stock appreciation right ("SAR") with respect to 492,537 shares of Issuer common stock, each at a premium exercise or grant price, as applicable, of $71.82. Both the option and the SAR become exercisable in three equal annual installments, with the first installment vesting on November 30, 2025. No change was made to the aggregate grant date value of the award, as reflected in the original Form 4 filed by the Reporting Person on December 3, 2024.

Content

On December 20, 2024, the Issuer made certain administrative modifications to the Reporting Person's November 30, 2024 grant agreement, confirming that the Reporting Person was granted a stock option to acquire 1,000,000 shares of Issuer common stock and a stock-settled stock appreciation right ("SAR") with respect to 492,537 shares of Issuer common stock, each at a premium exercise or grant price, as applicable, of $71.82. Both the option and the SAR become exercisable in three equal annual installments, with the first installment vesting on November 30, 2025. No change was made to the aggregate grant date value of the award, as reflected in the original Form 4 filed by the Reporting Person on December 3, 2024.